ECM
TCRX icon

ExodusPoint Capital Management’s TScan Therapeutics TCRX Stock Holding History

ExodusPoint Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-55,845
Closed -$278K – 2049
2024
Q3 		$278K Buy
+55,845
New +$337K ﹤0.01% 1386
2024
Q2 		– Sell
-35,661
Closed -$283K – 1974
2024
Q1 		$283K Sell
35,661
-28,117
-44% -$177K ﹤0.01% 1269
2023
Q4 		$372K Buy
+63,778
New +$292K ﹤0.01% 1116

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

ExodusPoint Capital Management's TCRX Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of TScan Therapeutics (TCRX) in Q4 2024, closing a stake of 55,845 shares — an estimated $278K sold.

ExodusPoint Capital Management first reported a position in TCRX in Q4 2023 and held it in 3 quarters. The position peaked at $372K in Q4 2023. 89 funds tracked by Wall St. Rank hold TCRX as of Q4 2024.

  • ExodusPoint Capital Management reported no remaining TScan Therapeutics position as of Q4 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 55,845 TScan Therapeutics shares in Q4 2024, an estimated $278K.
  • ExodusPoint Capital Management first reported a position in TScan Therapeutics in Q4 2023 and held it in 3 quarters.
  • ExodusPoint Capital Management's TScan Therapeutics position peaked at $372K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.